Patient-Controlled Analgesia Pumps Market is estimated to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
139
Patient-Controlled Analgesia Pumps Market is estimated to reflect a valuation of above US$ 500 Mn by 2026 - Future Market Insights

Valley Cottage, NY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- PCA or patient-controlled analgesia pumps is a way with which analgesic can be self-administered by the patient as and when needed. Patient-controlled analgesia pumps are not used to treat long term pains. PCA is used in various applications such as oncology or chemo therapy, pediatrics, gastroenterology, hematology and diabetes. There are several benefits of using PCA. It allows complete control on the pain treatment. It also assists in preventing the formation of blood clots and promotes healing at a faster rate. However, there are certain disadvantages, the main aspect being an occurrence of an over dost or an under dose that can take place in case of improper settings and programming of the device. Government initiatives to boost home medication, rising awareness about patient-controlled analgesia pumps, and affordable costs are few of the aspects contributing to the expansion of patient-controlled analgesia pumps market at a global level.

The global patient-controlled analgesia pumps market is projected to grow at a high CAGR during the period of forecast and is estimated to reflect a valuation of above US$ 500 Mn by the end of the year of forecast.

Global Patient-Controlled Analgesia Pumps Market: Dynamics

The growth of the global  patient-controlled analgesia pumps market  is influenced by aspects such as various advantages of PCA system over conventional continuous infusion systems, increasing standardization for reducing costs in hospitals, development of quality indicators for patient-controlled analgesia pumps, modernization with a view to reduce errors, increasing adoption of PCA owing to increasing prevalence of cancer, pain and diabetes, rising forward integration and increasing demand for PCA in rental and homecare services. These factors have contributed to the growth of the global market. On the contrary, lack of skilled manpower and lack of standard usage guidelines and vast product recalls are hampering the growth of the global patient-controlled analgesia pumps market. Various trends have been observed, to name a few, rapid med-tech progress, shifting production base to emerging economies, user-friendly advanced equipment and fragmented market. Opportunities such as increasing production base for smart pumps with bigger drug libraries and expanding production base for PCA, ambulatory and other pumps have been boosting the growth of the global market.

Get a Sample of this Research Report for more Industry Insights:   https://www.futuremarketinsights.com/reports/...ep-gb-5710

Segmental Highlights

The global patient-controlled analgesia pumps market has been segmented by product type, by end user, by application and by region.

By product type , the PCA pumps segment is estimated to be the largest segment in terms of market value and likely to lead the global market. it is also projected to grow at a higher pace thus reflecting high potential for growth of global market in the coming years.

By region , Asia Pacific excluding Japan (APEJ) region is projected to be the fastest growing with a high 9.6% CAGR during the forecast period. North America is the largest from a market share perspective.

By end user , hospitals segment is the most lucrative. This segment dominated the global market in 2017 and is expected to lead the market by 2026 end with a valuation of more than US$ 200 Mn.

By application , diabetes segment is the fastest growing segment with a high CAGR of 6.0% throughout the period of forecast.

The research report has also profiled various leading players in the global patient-controlled analgesia pumps market. Companies like Becton Dickinson and Company, Baxter International, B.Braun Melsungen AG, Terumo Corporation, Ace Medical Co. Ltd., Micrel Medical Devices, Hospira (Pfizer Inc.), Fresenius Kabi Group and Smiths Group plc., have been profiled in this research report.

Get Full Research Report on Patient-Controlled Analgesia Pumps:   https://www.futuremarketinsights.com/checkout/5710

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 F : +1-845-579-5705 T (UK): +44(0)20-7692-8790 Sales: sales@futuremarketinsights.com

Website : http://www.futuremarketinsights.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Ipsen's Kayfanda® Receives EU Approval for Alagille Syndrome Treatment

Updated Category News Views 67

Kayfanda® Receives Approval for Treatment in the EU Ipsen has made a noteworthy advancement in pediatric healthcare with the recent authorization of Kayfanda® (odevixibat) in the European Union (EU). This innovative treatment specifically addresses cholestatic pruritus, a painful symptom linked to Alagille Syndrome, a rare liver disorder that affects children. This...

Continue Reading
Discover the Remarkable Returns of Vulcan Materials Stock

Updated Category News Views 144

Unveiling Vulcan Materials Company Stock Performance Vulcan Materials Co. (NYSE: VMC) has been a noteworthy performer in the stock market over the past 15 years, surpassing market expectations with a commendable annual return of 15.1%. This stock has consistently outperformed the market, achieving an admirable 2.86% advantage annually. With a current market capitalization...

Continue Reading
AeroPress Launches Premium Coffee Press with Elegant Design

Updated Category News Views 332

AeroPress introduced its Premium coffee press back in 2024, and you can bet the market was watching closely. With a retail price of $149.95, this isn’t just another brewing tool; it’s a statement piece designed for those who take their morning ritual seriously. Traders buzzed about how this could impact sales in a saturated market where every new gadget fights for...

Continue Reading
Investigation Update: Walgreens Boots Alliance Class Action Lawsuit

Updated Category News Views 327

Overview of the Walgreens Boots Alliance Class Action Levi & Korsinsky, LLP has raised awareness among investors regarding a class action securities lawsuit involving Walgreens Boots Alliance, Inc. This company, known for its extensive pharmaceutical and retail operations, is currently facing legal challenges that could significantly impact its investors. Class Definition...

Continue Reading
Savillex Strengthens Market Position with New Acquisition

Updated Category News Views 38

Savillex Acquires Optimum Processing to Enhance Offerings Thompson Street Capital Partners (TSCP) is proud to announce that its portfolio company, Savillex, has completed the acquisition of Optimum Processing, Inc. This strategic move is expected to elevate Savillex's position in the marketplace by combining its innovative fluid handling solutions with Optimum...

Continue Reading